#industowers
Mkt leader telecom tower space in India, 95801 towers ~16% industry ,post merger 1,70,000 towers ,29% mkt share
Rev up 5.4% QoQ 37 bn,Rental up 3.4% QoQ 23.3 bn post rise in tenancy rates ,tenancy addition, energy rev up 9% 13.8 bn ,Ebidta margin down 130bps #telecom
PAT up 4% 7.3 bn
Net tenancy up 2116 vs decrease 365 in Q1 to 176332
5g infra rollout require dense network, however 5g more asset light, faster rollout,increase profitability
WFH ,Digitization,increased data consumption will sustain growth going fwd @airtelindia@reliancejio
Tenancy addition 2116 location is highest past 13 quarters
Post merger shareholding- Airtel 36.7 ,VIL 28.2 ,Providence 3.25 ,remaining public
Energy Ebidta loss due to operator shift from fixed energy to pass through model
Tenancy addtn to remain steady post Agr case #telecom
1 year cash flow from VIL from prepayment,Iry & 2ndry pledges
Jio building its own telecom infra,will lead to increased competition
Rentals per tenant per month up 3.3% to 43303 INR
Post merger Bharti infratel will not be Airtel subsidiary, FDI limit 100%
Receivables up due to deferment of exit payments, 800-900 crs dues pending
Receivables to decrease post merger
Dividend yield is healthy at 5%
Major contract renewals in 2023
Manag looking to bring operators back to fixed energy model
Capex spend to remain steady as Q2fy21 #Nifty
Company added 805 towers in 2018 ,826 in 2019 & 3095 in 2020, tower addtn to gather pace with 5g rollout ,WFH
Smart city project Bhopal with GOI on shared model of smart poles & optical fibres, cost 125 crs
Key risks- decreased data demand ,competition due to jio,land prices,5g
#industowers
M cap 63452 crs
CMP 235
P/E 22
BV 51
Yield 4.46%
ROCE 23%
FV 10
D/E 0.18
EV/EBIDTA 13.8
P/S 9.4
#glandpharma
Injectable focused B2B company
Mkt includes US,Europe,India,Australia
Niche area - sterile injectables,Oncology,Opthalmic solns
Focus -complex injectables,first to file,NCE-1, 505(b)(2) filings
Chinese promoter Shanghai Fosun Pharma is a global pharma major #pharma
Fosun acquired controlling stake in gland 74% in 2017 for $1.09 bn
Gland has 267 ANDA filings in the US Mkt, 215 approved
267 filings - 191 sterile injectables, 50 oncology ,26 ophthalmic
Out of 267,101 ANDA are owned by Gland of which 71 approved
Good regulatory compliance
No #USFDA warning letter till date
7 mftng facilities - 4 finished Formulations, 3 API
API facilities 100% captive consumption
63% of Fy20 revenue of 2633 cr were from US mkt
Focus on injs with high entry barrier, limited competition, strict regulatory reqs
Rise in gold prices led to robust gold jewellery & coin sales
Smaller towns driving demand
Recovery 77% in Jun to 98% in Sep quarter
50% Tanishq stores concentrated in rural areas
Wedding season ,diwali to further boost jewellery demand #titan#Nifty#sensex#StockMarket
Reopening of stores, malls, vaccine may increase footfalls in Q3,Q4
Launched 'Gift a Titan' & new jewellery division ' Rooted from Zoya'
Launched its 1st smartwatch 'Titan connected X'
Taneira launched 1st Chennai store ,total 13 stores functional
@IndianEnergyXch
Transformation drivers 1) Decarbonization - use of solar & wind ,RE (renewable energy) 2) Decentralisation - RE a threat to centralized energy productn 3) Digitization 4) Democratization- peer 2 peer energy trading
Changing energy mix 2020/ 2022 /2030 % of contribution
Thermal 62 /53 /35
Wind 10 /12 /17
Solar 9 / 20/ 36
Hydro 12 / 10 /8
Electricity value chain 4 parts
Generation - Transmission - Distribution - Consumption
Power sector construct
Long term 90%
Short term 10%
Power markets in developed countries are in range 30 - 80% of total power demand ,India 5%
Share of exchange in total generation
2016 - 2.9 %
2021 - 5.2%
Share of ST market in total generation
2016 - 9.9%
2021 - 10.3%
Exchange mkt & ST MKT as % of total gen
2016 29.9
2021 50.2
#Dixon key beneficiary of GOI PLI scheme
Through its subsidiary Padget electronics, Dixon made 2 applications for phones costing < 15000 ,70% India mobile mkt share
Incentive of 4 to 6% under PLI subject to a cap
Total investment 200crs ,50 cr/yr till 2025 #dixontechnologies
Post expansion revenue share of mobiles to jump to 44 from 12% currently
Ramp up capacity from 3 mn today to 15-16 mn over next few yrs ,aim for revenue 28-30000 crs over next 5 yrs
In talks 3 large players
Set top boxes, delivered 5.2 lakh to jio,dish,Citi
Order book 0.3mn/mon
Dixon is both OEM Player & ODM ( original design manufacturer)
Expanding capacities in Android & Linux TV ,semi automatic and top load washing machines
Current capacity 4 mn TV sets ,30%LED Mkt,acquired new customers Samsung,Nokia,Ramos capacity to 5.5 mn #Nifty#stocks
@JubilantLifeSci
Q2fy21 Revenue up 4.8% yoy to 2347.9 crs led by traction in CMO/Generics in Pharma & Life sciences in LSI segment
- Radiopharma business impacted by Covid & launch of macroaggregated Albumin (MAA) by competitor Curium(jubilant was sole player) #pharma#Nifty
MAA business witnessed price & mkt share erosion
-DTPA business impacted by decrease in ventilation scan due to covid
-Generic business growth led by traction existing products,launch of Remdesivir
-JLS to launch Remdesivir in 70 countries, exported API to US & injs in India
Radiopharma 90% & allergy business 100% precovid levels
-Partnership with SOFIE Biosciences in molecular theranostics
- JLS to double DDDS capacity by Fy22
- LSI business speciality declined 2% & nutritional grew 11% led by VIT D exports to EU while ethyl acetate muted growth
@GranulesIndia
Q2fy21
Revenue up 22.7% to 858 crs
Formulations up 22.4% yoy 430 crs
API up 17% to 255
PFI up 32.6% to 173 crs
Vizag unit V commissioned for API ,oncology segment,
Company plans gradual shift from commoditized API to more complex drugs/ Formulations #stocks
Company expects to commission MUPS block by Q3fy22
- Revenue contribution of core mols dropped to 70 from 80-85% end of Fy20
- #granules has 32 ANDA approved ,expect to launch 6 of these in Fy21
- Revised PAT guidance to 30% post Fy21 from 25% earlier #StockMarket#Nifty
Company plans 7-9 product filings/year, atleast 5 for the US market
- Top 5 mols contributed 70%
- Capex guidance of 3.5 to 4 bn for fy21 & 3bn for Fy22
- Relaunch Metformin 750 mg in US over next year
- EU sales 23 % expected to reach 28% by Fy23, US sales to decline to 43%